http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014138626-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3015 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6817 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6871 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-07 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014138626-A |
| titleOfInvention | THE MODIFIED ANTIBODIES TO WHICH THE MOTIV IS RELATED, INCLUDING THE RESIDUE OF CISTEINE, THE CONJUGATES OF THESE MODIFIED ANTIBODIES WITH MEDICINES AND THE METHOD FOR PRODUCING THEM |
| abstract | 1. A modified antibody that at the end of the molecule contains a cysteine-containing motif having the structure represented by formula 1 below: where (M) is a cysteine residue or peptide motif containing a cysteine residue and having a specific function or having a specific secondary or tertiary structure; Xa and Xb, independently of each other, each represents a peptide containing from 0 to 20 amino acid residues other than cysteine; n is an integer from 1 to 20.2. The modified antibody of claim 1, wherein the cysteine-containing motif having the structure represented by the above formula 1 is linked to the end of the heavy chain of the parent antibody. The modified antibody of claim 2, wherein the cysteine-containing motif having the structure represented by the above formula 1 is linked to the C-terminus of the heavy chain of the parent antibody. The modified antibody of claim 1, wherein said peptide motif having a specific function or having a specific secondary or tertiary structure is one or more selected from the group consisting of: CH group (CysHis class: Cys-X-Cys-X-His -X-His), group C (class C4: Cys-X-Cys-X-Cys-X-Cys-X-Cys-X-Cys-X-Cys-X-Cys) or group C (class C6: Cys -X-Cys-X-Cys-X-Cys-X-Cys-X-Cys) proteins with zinc fingers; a metal ion binding motif artificially based on a zinc finger motif or a metal ion binding protein motif; Cys-X motif -Cys, Met-X-Cys-XX-Cys motif or C-Q-C-Q-C-A-C motif of proteins - transcriptional regulators, metallapaperon proteins, metal ion transporters or superoxide dismutase proteins; Ser-Pro-Cys motif of membrane ATPase; peptide motif that binds metal ions with a ring structure; having CGH or HGC, (where in the structure of the peptide motif described above with specific |
| priorityDate | 2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 356.